Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 11/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.45 |
| ▸ | ITGAV | P06756 | 8/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.37 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431255 | 1.00 | ITGB1 (0.50) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL5207016 | 0.93 | ITGB1 (0.42) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL14431257 | 0.93 | ITGB1 (0.42) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL3046466 | 0.86 | ITGB3 (0.39) | ITGB1ITGA5ITGB3ITGAVITGA2B | |
| SCHEMBL14431276 | 0.86 | ITGB3 (0.39) | ITGB1ITGA5ITGB3ITGAVITGA2B | |
| SCHEMBL13170302 | 0.85 | ITGB1 (0.49) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL6496052 | 0.84 | ITGB1 (0.47) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL6498071 | 0.84 | ITGB3 (0.44) | ITGB3ITGAVITGA2BTYR | |
| SCHEMBL13170301 | 0.84 | ITGB1 (0.53) | ITGB1ITGA5MDM4MDM2ITGB3 | |
| SCHEMBL3048231 | 0.84 | ITGB3 (0.45) | ITGB1ITGA5ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124824-B1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2007-08-22 | — | — | EP | claimed |
| EP-1411926-B1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2005-06-01 | — | — | EP | claimed |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | MERCK PATENT GMBH (DE) | 2005-04-21 | — | — | US | claimed |
| US-6849646-B1 | Chromenone and chromanone derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2005-02-01 | — | — | US | claimed |
| EP-1474162-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GmbH (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | MERCK PATENT GESELLSCHAFT (DE) | 2004-10-07 | — | — | US | claimed |
| US-20040029788-A1 | Methods and compositions for the treatment of diseases of the eye | MERCK PATENT GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| EP-1381382-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GmbH (DE) | 2004-01-21 | — | — | EP | claimed |
| WO-2003068253-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | WO | claimed |
| WO-2002041910-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | claimed |
| US-7648959-B2 | Methods and compositions for the treatment of diseases of the eye | MERCK PATENT GMBH (DE) | 2010-01-19 | — | — | US | disclosed |
| US-7645736-B2 | injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid | MERCK PATENT GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| EP-1124824-B1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | SCRIPPS RESEARCH INSTITUTE, THE | 2006-12-21 | — | — | US | disclosed |
| US-20060223746-A1 | Methods and compositions for the treatment of diseases of the eye | SCRIPPS RESEARCH INSTITUTE, THE | 2006-10-05 | — | — | US | disclosed |
| EP-1381382-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GmbH (DE) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003013511-A1 | INTEGRIN INHIBITORS FOR THE TREATMENT OF EYE DISEASES | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002041910-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OF THE EYE | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
| EP-1124824-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026212-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198644-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB1 6/4885ITGA5 1/4885MDM4 4368/4885 |
| US-20060287225-A1 | Integrin inhibitors for the treatment of eye diseases | ITGA5, ITGAV, ITGB5 | ITGB1 5/4885ITGA5 1/4885MDM4 4570/4885 |
| US-20060223746-A1 | Methods and compositions for the treatment of diseases of the eye | ITGA5, ITGAV, ITGB5 | ITGB1 7/4885ITGA5 1/4885MDM4 4698/4885 |
| US-20040029788-A1 | Methods and compositions for the treatment of diseases of the eye | ITGA5, ITGAV, ITGB3 | ITGB1 7/4885ITGA5 1/4885MDM4 4674/4885 |
| US-20050085415-A1 | Methods and compositions for the treatment of eye diseases | ITGA5, ITGB5, ITGAV | ITGB1 14/4885ITGA5 1/4885MDM4 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.